Eversept Partners LP bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 155,540 shares of the biopharmaceutical company's stock, valued at approximately $6,097,000. Eversept Partners LP owned approximately 0.20% of Xenon Pharmaceuticals at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of XENE. Blue Trust Inc. raised its position in shares of Xenon Pharmaceuticals by 140.3% during the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after buying an additional 1,414 shares in the last quarter. Avior Wealth Management LLC bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth about $101,000. KBC Group NV boosted its holdings in shares of Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 780 shares in the last quarter. Magnetar Financial LLC bought a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at about $210,000. Finally, HighMark Wealth Management LLC lifted its position in Xenon Pharmaceuticals by 22.0% in the 4th quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company's stock worth $239,000 after buying an additional 1,100 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors.
Xenon Pharmaceuticals Stock Performance
XENE stock traded up $0.61 on Thursday, reaching $38.20. The company's stock had a trading volume of 637,044 shares, compared to its average volume of 443,256. The business has a fifty day simple moving average of $34.83 and a two-hundred day simple moving average of $38.71. The firm has a market cap of $2.92 billion, a PE ratio of -13.55 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.05. As a group, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
XENE has been the subject of a number of research reports. Royal Bank of Canada reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Deutsche Bank Aktiengesellschaft initiated coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price objective on the stock. William Blair restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. StockNews.com raised Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Finally, The Goldman Sachs Group dropped their price objective on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $56.78.
Read Our Latest Report on Xenon Pharmaceuticals
Insider Buying and Selling
In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of the business's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the sale, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at approximately $1,258,340.40. The trade was a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.52% of the stock is currently owned by insiders.
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Articles
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
